Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection

Intervirology

Volumn 46, Issue 6, 2003, Pages 388-393

  Lee, Han Chu ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Hepatitis B virus; Lamivudine; Liver cirrhosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; HEPATITIS B ANTIBODY; LAMIVUDINE;

CONFERENCE PAPER; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; HEPATITIS B; HUMAN; INFLAMMATION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX;

HEPATITIS B VIRUS;

EID: 0346156073     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074997     Document Type: Conference Paper

References (44)

1. Lee HS, Kim CY: Seroepidemiology of HBV and HCV in Korea: The decreasing prevalence rate of HBV infection after launching HB vaccination program. Int Hepatol Commun 1996;5:53-61.
2. Kim CY, Lee HS, Han CJ: Relative etiologic role of hepatitis B virus and hepatitis C virus in chronic liver diseases and hepatocellular carcinoma among age-specific groups in Korea: The possible presence of non-B, non-C agents. Seoul J Med 1993;34:27-33.
3. Hoofnagle JH, Shafritz DA, Popper H: Chronic type B hepatitis and the 'healthy' HBsAg carrier state. Hepatology 1987;7:758-763.
4. Lok AS, Chung HT, Liu VW, Ma OC: Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838.
5. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975.
6. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS: Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
7. Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, Kim YS, Park K, Kim DK, Moon YM: Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000;31:1371-1373.
8. Kao JH: Hepatitis B viral genotypes: Clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
9. Lee SH, Han SH, Cho SC, Roh BJ, Sohn JH, Kim DA, Lee DH, Kee CS: Distribution of HBV genotypes in patients with chronic HBV infection in Korea (in Korean). Taehan Kan Hakhoe Chi 2001;7:373-380.
10. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002.
11. Kao JH, Liu CJ, Chen DS: Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002;36:303-304.
12. Chien RN, Liaw YF, Tsai SL, Yeh CT, Chu CM: HBV genotype is the major factor for durability of HBeAg response to lamivudine therapy (abstract). Gastroenterology 2002;123:T1359.
13. Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO, Lai CL: Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003;37:562-567.
14. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-1856.
15. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
16. Kim CY, Kim JW, Lee HS, Yoon YB, Song IS: Natural history and survival rate of chronic liver diseases in Korea. Korean J Intern Med 1994;46:168-180.
17. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
18. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EURO-HEP). Hepatology 1997;26:1338-1342.
19. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
20. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-145.
21. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, Bodicky C, Miller B, Denham C, et al: Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-916.
22. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
23. Chang CN, Skalski V, Zhou JH, Cheng YC: Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-22420.
24. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
25. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
26. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
27. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK: Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308-312.
28. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
29. Yao FY, Bass NM: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-307.
30. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
31. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
32. Jung S, Suh DJ, Park HJ, Park YH, Song HG, Lee HC, Chung YH, Lee YS: Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea (in Korean). Taehan Kan Hakhoe Chi 2002;8:418-427.
33. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, Soldevila-Pico C, McClure LA, Lok AS: Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-439.
34. Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ: The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002;9:424-428.
35. Chien RN, Lin CH, Liaw YF: The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 2003;38:322-327.
36. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA: Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-727.
37. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
38. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, Neuhaus R, Berg T, Hopf U, Neuhaus P: Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-1535.
39. Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-633.
40. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
41. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY: Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate- aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-405.
42. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, Hardy D, Beall G, Cooper R, Murphy R, Basgoz N, Ng E, Deeks S, Winslow D, Toole JJ, Coakley D: Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 1999;282:2305-2312.
43. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, Bismuth H: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815.
44. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H: Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.